
Lupin Pharmaceuticals has launched a generic inhalation powder for treating COPD in the U.S. Tiotropium bromide inhalation powder is a generic equivalent of Spiriva Handihaler inhalation powder from Boehringer Ingelheim Pharmaceuticals Inc.
Vinita Gupta, Lupin CEO, said the launch extends accessibility to inhalers and will help alleviate the burden of COPD for patients.
“This launch is a testament to our commitment to advancing health care accessibility and is a result of years of hard work and dedication to building our complex products and respiratory franchise,” she said. “Being the first to bring an FDA-approved, generic version of Spiriva in the U.S. further reaffirms our commitment to enhancing the well-being of COPD patients for a healthier future.”
Earlier this year, the company received approval for the use of the product in Canada from Health Canada.
Tiotropium bromide inhalation powder is indicated in Canada for the long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with COPD. This also includes bronchitis and emphysema. It is not used for treating sudden breathing problems.